Excess TGF-β mediates muscle weakness associated with bone metastases in mice

David L. Waning, Khalid Mohammad, Steven Reiken, Wenjun Xie, Daniel C. Andersson, Sutha John, Antonella Chiechi, Laura Wright, Alisa Umanskaya, Maria Niewolna, Trupti Trivedi, Sahba Charkhzarrin, Pooja Khatiwada, Anetta Wronska, Ashley Haynes, Maria Serena Benassi, Frank Witzmann, Gehua Zhen, Xiao Wang, Xu CaoG. David Roodman, Andrew R. Marks, Theresa Guise

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Cancer-associated muscle weakness is a poorly understood phenomenon, and there is no effective treatment. Here we find that seven different mouse models of human osteolytic bone metastases - representing breast, lung and prostate cancers, as well as multiple myeloma - exhibited impaired muscle function, implicating a role for the tumor-bone microenvironment in cancer-associated muscle weakness. We found that transforming growth factor (TGF)-β, released from the bone surface as a result of metastasis-induced bone destruction, upregulated NADPH oxidase 4 (Nox4), resulting in elevated oxidization of skeletal muscle proteins, including the ryanodine receptor and calcium (Ca 2+) release channel (RyR1). The oxidized RyR1 channels leaked Ca 2+, resulting in lower intracellular signaling, which is required for proper muscle contraction. We found that inhibiting RyR1 leakage, TGF-β signaling, TGF-β release from bone or Nox4 activity improved muscle function in mice with MDA-MB-231 bone metastases. Humans with breast- or lung cancer-associated bone metastases also had oxidized skeletal muscle RyR1 that is not seen in normal muscle. Similarly, skeletal muscle weakness, increased Nox4 binding to RyR1 and oxidation of RyR1 were present in a mouse model of Camurati-Engelmann disease, a nonmalignant metabolic bone disorder associated with increased TGF-β activity. Thus, pathological TGF-β release from bone contributes to muscle weakness by decreasing Ca 2+ -induced muscle force production.

Original languageEnglish (US)
Pages (from-to)1262-1271
Number of pages10
JournalNature Medicine
Volume21
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Muscle Weakness
Transforming Growth Factors
Ryanodine Receptor Calcium Release Channel
Muscle
Bone
Neoplasm Metastasis
Bone and Bones
NADPH Oxidase
Muscle Neoplasms
Muscles
Skeletal Muscle
Lung Neoplasms
Camurati-Engelmann Syndrome
Breast Neoplasms
Bone Neoplasms
Tumor Microenvironment
Muscle Proteins
Muscle Contraction
Multiple Myeloma
Prostatic Neoplasms

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Excess TGF-β mediates muscle weakness associated with bone metastases in mice. / Waning, David L.; Mohammad, Khalid; Reiken, Steven; Xie, Wenjun; Andersson, Daniel C.; John, Sutha; Chiechi, Antonella; Wright, Laura; Umanskaya, Alisa; Niewolna, Maria; Trivedi, Trupti; Charkhzarrin, Sahba; Khatiwada, Pooja; Wronska, Anetta; Haynes, Ashley; Benassi, Maria Serena; Witzmann, Frank; Zhen, Gehua; Wang, Xiao; Cao, Xu; Roodman, G. David; Marks, Andrew R.; Guise, Theresa.

In: Nature Medicine, Vol. 21, No. 11, 01.11.2015, p. 1262-1271.

Research output: Contribution to journalArticle

Waning, DL, Mohammad, K, Reiken, S, Xie, W, Andersson, DC, John, S, Chiechi, A, Wright, L, Umanskaya, A, Niewolna, M, Trivedi, T, Charkhzarrin, S, Khatiwada, P, Wronska, A, Haynes, A, Benassi, MS, Witzmann, F, Zhen, G, Wang, X, Cao, X, Roodman, GD, Marks, AR & Guise, T 2015, 'Excess TGF-β mediates muscle weakness associated with bone metastases in mice', Nature Medicine, vol. 21, no. 11, pp. 1262-1271. https://doi.org/10.1038/nm.3961
Waning, David L. ; Mohammad, Khalid ; Reiken, Steven ; Xie, Wenjun ; Andersson, Daniel C. ; John, Sutha ; Chiechi, Antonella ; Wright, Laura ; Umanskaya, Alisa ; Niewolna, Maria ; Trivedi, Trupti ; Charkhzarrin, Sahba ; Khatiwada, Pooja ; Wronska, Anetta ; Haynes, Ashley ; Benassi, Maria Serena ; Witzmann, Frank ; Zhen, Gehua ; Wang, Xiao ; Cao, Xu ; Roodman, G. David ; Marks, Andrew R. ; Guise, Theresa. / Excess TGF-β mediates muscle weakness associated with bone metastases in mice. In: Nature Medicine. 2015 ; Vol. 21, No. 11. pp. 1262-1271.
@article{b31c291c0ed74b31be6b25ac537c934f,
title = "Excess TGF-β mediates muscle weakness associated with bone metastases in mice",
abstract = "Cancer-associated muscle weakness is a poorly understood phenomenon, and there is no effective treatment. Here we find that seven different mouse models of human osteolytic bone metastases - representing breast, lung and prostate cancers, as well as multiple myeloma - exhibited impaired muscle function, implicating a role for the tumor-bone microenvironment in cancer-associated muscle weakness. We found that transforming growth factor (TGF)-β, released from the bone surface as a result of metastasis-induced bone destruction, upregulated NADPH oxidase 4 (Nox4), resulting in elevated oxidization of skeletal muscle proteins, including the ryanodine receptor and calcium (Ca 2+) release channel (RyR1). The oxidized RyR1 channels leaked Ca 2+, resulting in lower intracellular signaling, which is required for proper muscle contraction. We found that inhibiting RyR1 leakage, TGF-β signaling, TGF-β release from bone or Nox4 activity improved muscle function in mice with MDA-MB-231 bone metastases. Humans with breast- or lung cancer-associated bone metastases also had oxidized skeletal muscle RyR1 that is not seen in normal muscle. Similarly, skeletal muscle weakness, increased Nox4 binding to RyR1 and oxidation of RyR1 were present in a mouse model of Camurati-Engelmann disease, a nonmalignant metabolic bone disorder associated with increased TGF-β activity. Thus, pathological TGF-β release from bone contributes to muscle weakness by decreasing Ca 2+ -induced muscle force production.",
author = "Waning, {David L.} and Khalid Mohammad and Steven Reiken and Wenjun Xie and Andersson, {Daniel C.} and Sutha John and Antonella Chiechi and Laura Wright and Alisa Umanskaya and Maria Niewolna and Trupti Trivedi and Sahba Charkhzarrin and Pooja Khatiwada and Anetta Wronska and Ashley Haynes and Benassi, {Maria Serena} and Frank Witzmann and Gehua Zhen and Xiao Wang and Xu Cao and Roodman, {G. David} and Marks, {Andrew R.} and Theresa Guise",
year = "2015",
month = "11",
day = "1",
doi = "10.1038/nm.3961",
language = "English (US)",
volume = "21",
pages = "1262--1271",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Excess TGF-β mediates muscle weakness associated with bone metastases in mice

AU - Waning, David L.

AU - Mohammad, Khalid

AU - Reiken, Steven

AU - Xie, Wenjun

AU - Andersson, Daniel C.

AU - John, Sutha

AU - Chiechi, Antonella

AU - Wright, Laura

AU - Umanskaya, Alisa

AU - Niewolna, Maria

AU - Trivedi, Trupti

AU - Charkhzarrin, Sahba

AU - Khatiwada, Pooja

AU - Wronska, Anetta

AU - Haynes, Ashley

AU - Benassi, Maria Serena

AU - Witzmann, Frank

AU - Zhen, Gehua

AU - Wang, Xiao

AU - Cao, Xu

AU - Roodman, G. David

AU - Marks, Andrew R.

AU - Guise, Theresa

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Cancer-associated muscle weakness is a poorly understood phenomenon, and there is no effective treatment. Here we find that seven different mouse models of human osteolytic bone metastases - representing breast, lung and prostate cancers, as well as multiple myeloma - exhibited impaired muscle function, implicating a role for the tumor-bone microenvironment in cancer-associated muscle weakness. We found that transforming growth factor (TGF)-β, released from the bone surface as a result of metastasis-induced bone destruction, upregulated NADPH oxidase 4 (Nox4), resulting in elevated oxidization of skeletal muscle proteins, including the ryanodine receptor and calcium (Ca 2+) release channel (RyR1). The oxidized RyR1 channels leaked Ca 2+, resulting in lower intracellular signaling, which is required for proper muscle contraction. We found that inhibiting RyR1 leakage, TGF-β signaling, TGF-β release from bone or Nox4 activity improved muscle function in mice with MDA-MB-231 bone metastases. Humans with breast- or lung cancer-associated bone metastases also had oxidized skeletal muscle RyR1 that is not seen in normal muscle. Similarly, skeletal muscle weakness, increased Nox4 binding to RyR1 and oxidation of RyR1 were present in a mouse model of Camurati-Engelmann disease, a nonmalignant metabolic bone disorder associated with increased TGF-β activity. Thus, pathological TGF-β release from bone contributes to muscle weakness by decreasing Ca 2+ -induced muscle force production.

AB - Cancer-associated muscle weakness is a poorly understood phenomenon, and there is no effective treatment. Here we find that seven different mouse models of human osteolytic bone metastases - representing breast, lung and prostate cancers, as well as multiple myeloma - exhibited impaired muscle function, implicating a role for the tumor-bone microenvironment in cancer-associated muscle weakness. We found that transforming growth factor (TGF)-β, released from the bone surface as a result of metastasis-induced bone destruction, upregulated NADPH oxidase 4 (Nox4), resulting in elevated oxidization of skeletal muscle proteins, including the ryanodine receptor and calcium (Ca 2+) release channel (RyR1). The oxidized RyR1 channels leaked Ca 2+, resulting in lower intracellular signaling, which is required for proper muscle contraction. We found that inhibiting RyR1 leakage, TGF-β signaling, TGF-β release from bone or Nox4 activity improved muscle function in mice with MDA-MB-231 bone metastases. Humans with breast- or lung cancer-associated bone metastases also had oxidized skeletal muscle RyR1 that is not seen in normal muscle. Similarly, skeletal muscle weakness, increased Nox4 binding to RyR1 and oxidation of RyR1 were present in a mouse model of Camurati-Engelmann disease, a nonmalignant metabolic bone disorder associated with increased TGF-β activity. Thus, pathological TGF-β release from bone contributes to muscle weakness by decreasing Ca 2+ -induced muscle force production.

UR - http://www.scopus.com/inward/record.url?scp=84946203483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946203483&partnerID=8YFLogxK

U2 - 10.1038/nm.3961

DO - 10.1038/nm.3961

M3 - Article

C2 - 26457758

AN - SCOPUS:84946203483

VL - 21

SP - 1262

EP - 1271

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 11

ER -